Targeting MET in cancer therapy
MET encodes a receptor tyrosine kinase c-MET for hepatocyte growth factor (HGF). The specific combination of c-MET and HGF activates downstream signaling pathways to trigger cell migration, proliferation, and angiogenesis. MET exon 14 alterations and MET gene amplification play a critical role in th...
Guardado en:
Autores principales: | Hong-Nan Mo, Peng Liu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
KeAi Communications Co., Ltd.
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/de222e61f8fd42a8a74c780b8dd370cb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Progress in targeted therapy for breast cancer
por: Jie Ju, et al.
Publicado: (2018) -
Ovarian cancer: emerging molecular-targeted therapies
por: Sourbier C
Publicado: (2012) -
Targeted therapy using nanotechnology: focus on cancer
por: Sanna V, et al.
Publicado: (2014) -
A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer
por: Deng L, et al.
Publicado: (2012) -
Folate-targeted docetaxel-lipid-based-nanosuspensions for active-targeted cancer therapy
por: Wang L, et al.
Publicado: (2012)